Evidence map›Paper›PMID 39162787›Full record

ArticleOncology nursing forum2024

Exploring Analgesic Use Patterns Among Cancer Survivors With Chronic Chemotherapy-Induced Peripheral Neuropathy.

Robert Knoerl, Michael B Sohn, Melyssa Foust, Lori Francar, Mark A O'Rourke, Gary M Morrow, Karen M Mustian, Lynn Gauthier, Jennifer S Gewandter

Abstract read
In one paragraph

Article in Oncology nursing forum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Robert KnoerlUniversity of Michigan in Ann Arbor.
Michael B SohnUniversity of Rochester Medical Center.
Melyssa FoustUpstate Carolina Consortium National Cancer Institute Community Oncology Research Program.
Lori FrancarHospital Sisters Health System St. Vincent Hospital.
Mark A O'RourkeUniversity of South Carolina.
Gary M MorrowUniversity of Rochester Medical Center.
Karen M MustianUniversity of Rochester Medical Center.
Lynn GauthierUniversité Laval.
Jennifer S GewandterUniversity of Rochester Medical Center.

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Wireless transcutaneous electrical stimulation (TENS) for chemotherapy-induced peripheral neuropathy: A phase II randomized clinical trialR21CA235389 · NCI · UNIVERSITY OF ROCHESTER · PI GEWANDTER, JENNIFER · 2019 to 2020
$363k
Promoting high-quality pain treatment trials through mentorship of junior investigators: A focus on study conduct and method developmentK24NS126861 · NINDS · UNIVERSITY OF ROCHESTER · PI GEWANDTER, JENNIFER · 2021 to 2021
$306k
NCI NIH HHS R21 CA235389NCI NIH HHS UG1 CA189961NINDS NIH HHS K24 NS126861
6 · The paper itself

Abstract

objectivesTo explore cancer survivors' historical and current use of analgesics for chronic chemotherapy-induced peripheral neuropathy (CIPN). SAMPLE &

setting142 post-treatment cancer survivors who received neurotoxic chemotherapy and were experiencing moderate to severe CIPN. METHODS & VARIABLES: Participants completed the Treatment-Induced Neuropathy Assessment Scale at baseline and reported all analgesics used to manage CIPN. Frequency of historical or current prescription analgesic use for chronic CIPN was described and stratified by CIPN pain severity.

resultsAt baseline, 31% of participants reported historical use of analgesics for CIPN and 46% of participants were currently using analgesics for CIPN. Gabapentin was the most frequently used analgesic, historically (20%) and currently (34%), and duloxetine was used less frequently (6% historical use, 10% current use). Many participants with severe pain (59%) reported using analgesics for CIPN. IMPLICATIONS FOR NURSING: Duloxetine, the first-line treatment for chronic CIPN pain, was used less frequently than gabapentin, a common prescription analgesic for neuropathic pain. Further research is needed to determine strategies to promote the implementation of evidence-based CIPN treatments in clinical practice.

Indexed as

AnalgesicsAntineoplastic AgentsCancer SurvivorsDuloxetine HydrochlorideNeoplasmsPeripheral Nervous System DiseasesAdultAgedAged, 80 and overFemaleGabapentinHumansMaleMiddle AgedNeuralgiaAnalgesicsAntineoplastic AgentsDuloxetine HydrochlorideGabapentinanalgesicscancer painchemotherapy-induced peripheral neuropathy

Identifiers

PMID39162787
PMCPMC11626725

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.